Research Article
Assessment of cognition in mild cognitive impairment: A comparative study

Peter J. Snyder, Colleen E. Jackson, Ronald C. Petersen, Ara S. Khachaturian, Jeffrey Kaye, Marilyn S. Albert and Sandra Weintraub

Alzheimer`s & Dementia, 2011, 7(3), 338-355. DOI: 10.1016/j.jalz.2011.03.009

Abstract

The demand for rapidly administered, sensitive, and reliable cognitive assessments that are specifically designed for identifying individuals in the earliest stages of cognitive decline (and to measure subtle change over time) has escalated as the emphasis in Alzheimer‘s disease clinical research has shifted from clinical diagnosis and treatment toward the goal of developing presymptomatic neuroprotective therapies. To meet these changing clinical requirements, cognitive measures or tailored batteries of tests must be validated and determined to be fit-for-use for the discrimination between cognitively healthy individuals and persons who are experiencing very subtle cognitive changes that likely signal the emergence of early mild cognitive impairment. We sought to collect and review data systematically from a wide variety of (mostly computer-administered) cognitive measures, all of which are currently marketed or distributed with the claims that these instruments are sensitive and reliable for the early identification of disease or, if untested for this purpose, are promising tools based on other variables. The survey responses for 16 measures/batteries are presented in brief in this review; full survey responses and summary tables are archived and publicly available on the Campaign to Prevent Alzheimer‘s Disease by 2020 Web site (http://pad2020.org). A decision tree diagram highlighting critical decision points for selecting measures to meet varying clinical trials requirements has also been provided. Ultimately, the survey questionnaire, framework, and decision guidelines provided in this review should remain as useful aids for the evaluation of any new or updated sets of instruments in the years to come.

ASCI-ID: 285-144

View Fulltext

Similar Articles


Social vulnerability predicts cognitive decline in a prospective cohort of older Canadians

Alzheimer`s & Dementia, 2010, 6(4), 319-325. DOI: 10.1016/j.jalz.2009.11.001

The pattern of cognitive symptoms predicts time to dementia onset

Alzheimer`s & Dementia, 2009, 5(3), 199-206. DOI: 10.1016/j.jalz.2008.10.007

Fourteen-year longitudinal study of vascular risk factors, APOE genotype, and cognition: The ARIC MRI Study

Alzheimer`s & Dementia, 2009, 5(3), 207-214. DOI: 10.1016/j.jalz.2009.01.027

Outcome over seven years of healthy adults with and without subjective cognitive impairment

Alzheimer`s & Dementia, 2010, 6(1), 11-24. DOI: 10.1016/j.jalz.2009.10.002

Predictors of costs of care in Alzheimer‘s disease: A multinational sample of 1222 patients

Alzheimer`s & Dementia, 2011, 7(3), 318-327. DOI: 10.1016/j.jalz.2010.09.001

Intraindividual cognitive decline using a brief computerized cognitive screening test

Alzheimer`s & Dementia, 2012, 8(2), 95-104. DOI: 10.1016/j.jalz.2010.12.009

A homopolymer polymorphism in the TOMM40 gene contributes to cognitive performance in aging

Alzheimer`s & Dementia, 2012, 8(5), 381-388. DOI: 10.1016/j.jalz.2011.10.005

Frailty syndrome and the risk of vascular dementia: The Italian Longitudinal Study on Aging

Alzheimer`s & Dementia, 2013, 9(2), 113-122. DOI: 10.1016/j.jalz.2011.09.223

Homocysteine, progression of ventricular enlargement, and cognitive decline: The Second Manifestations of ARTerial disease–Magnetic Resonance study

Alzheimer`s & Dementia, 2013, 9(3), 302-309. DOI: 10.1016/j.jalz.2011.11.008

Scales as outcome measures for Alzheimer's disease

Alzheimer`s & Dementia, 2009, 5(4), 324-339. DOI: 10.1016/j.jalz.2009.05.667

Cognitive correlates of cerebrospinal fluid biomarkers in frontotemporal dementia

Alzheimer`s & Dementia, 2013, 9(3), 269-275. DOI: 10.1016/j.jalz.2011.12.007